1 The purpose of these experiments was to investigate the effects of the selective peptidoleukotriene receptor antagonist, SK&F S-106203, on leukotriene C4 (LTC4), LTD4 and LTE4 vasopressor responses in the conscious, normotensive rat. SK&F S-106203 was administered as a bolus followed by a continuous infusion in order to provide information on the relationship between antagonism of leukotriene responses and steady-state plasma concentrations. 2 Infusion of SK&F S-106203 at doses of 0.2 mg kg + I mg kg h, 1 mg kg + 3 mg kg1h -' or 2 mg kg'-+ 10 mg kg -h -' produced dose-dependent steady-state plasma drug concentrations of 1.0, 3.2 and 23.8/.tgml-1, respectively. Plasma SK&F S-106203 concentrations appeared to increase in a linear fashion at doses of 1 and 3 mg kg'-h -'; at the highest dose the increment in plasma drug concentrations (i.e., 7-8 fold) was greater than the increment in dose (i.e., 3 fold), suggesting saturation of the primary clearance mechanism(s) at this dose. 3 SK&F S-106203 (2mgkg-1 + l0mgkg-'h-1) had no effect on noradrenaline-, vasopressin-, isoprenaline-, or U 46619-induced responses. 4 SK&F S-106203 produced dose-dependent rightward shifts in the LTC4 and LTE4 dose-response curves. Administration of SK&F S-106203 at doses of 0.2mg kg1 + 1 mg kg1 h-, mg kg' + 3mgkg-'h-1, or 2mgkg-' + lOmgkg-1h'-produced dose-ratios of 1.0, 3.1 and 19.9, respectively, against LTC4 responses, and dose-ratios of 1.6, 3.8 and 9.1, respectively, against LTE4 responses. 5 Against LTD4 responses, SK&F S-106203 at doses of 0.2mgkg -+ mgkg-1 h-, mg kg' + 3 mg kg-1h -', or 2 mg kg -+ 10 mg kg -h -produced dose-ratios of 2.5, 2.8, and 11.4, respectively. Administration of D-penicillamine, a non-competitive LTD4 dipeptidase inhibitor, had no effect on LTD4 responses.
Introduction
The investigation of the role of the peptidoleukotrienes leukotriene C4 (LTC4), LTD4 and LTE4 in asthma, allergic reac- tions and inflammatory cell responses is an area of intensive activity (Weiss et al., 1982; Samuelsson, 1983) . More recently, attention has focused on the role these putative mediators may have in cardiovascular disorders, such as myocardial reperfusion injury, renal failure and circulatory shock. LTC4, LTD4, and LTE4 have been shown to increase vascular permeability (Dahlen et a1., 1981) , and have potent effects on various smooth muscle preparations, including trachea (Fleisch et al., 1982; Hay et al., 1987) , the small intestine (Fleisch et al., 1982) , and coronary and mesenteric vessels (Michelassi et al., 1982; Woodman & Dusting, 1983; Roth & Lefer, 1983; Eimerl et al., 1986) . The pathophysiological responses to peptidoleukotrienes, such as contraction of smooth muscle and increased vascular permeability, would exacerbate conditions such as myocardial ischaemia, circulatory shock and inflammatory disorders.
In order to clarify the precise role of peptidoleukotrienes in cardiovascular or other disorders, highly potent (Boyd et al., 1983) , and to inhibit cyclic nucleotide phosphodiesterase (Hay et al., 1987) . SK&F S-I Author for correspondence.
106203 is representative of a class of peptidoleukotriene receptor antagonists that are structurally similar to the natural agonist. Like similar molecules such as SK&F 102922 and SK&F 104353, SK&F S-106203 is a potent and selective receptor antagonist . However, SK&F S-106203, unlike many of its structural analogues, appears to have high oral bioavailability . A peptidoleukotriene receptor antagonist with high oral bioavailability, such as SK&F S-106203, could be useful for probing the role of leukotrienes in respiratory diseases, as well as other diseases where peptidoleukotrienes have been implicated as important mediators, such as endotoxic and septic shock, and myocardial reperfusion injury, where high systemic concentrations of antagonist may be required to antagonize the effect of leukotrienes. As a prelude to such studies, it is imperative to document the plasma concentrations of SK&F S-106203 required to antagonize a peptidoleukotriene response. Therefore, the purpose of this study was to characterize the effects of SK&F S-106203 on the vascular responses to LTC4, LTD4 and LTE4. These studies were conducted in conscious, chronically instrumented rats in order to avoid the confounding influences of acute surgical preparation and anaesthetic agents.
Methods

Animal preparation
Male Sprague-Dawley rats, weighing 320-395 g, were anaesthetized with pentobarbitone sodium (30mgkg-1, i.p.) and prepared, with modifications, as described previously . Briefly, catheters were placed into the vena cava and abdominal aorta through the left and right femoral veins and left femoral artery, respectively. The catheters were led subcutaneously along the tail and exteriorized through an incision 5cm from the base of the tail. A 10ml syringe barrel, with the closed end removed, was placed over the tail and secured with tape. The syringe barrel served to protect the incision site and catheters. The animals were housed in individual cages and the syringe barrel used to tether the animals. Catheter patency was maintained with an infusion of 0.9% NaCl containing 2.4uml-1 heparin at a rate of 0.6mlh-. Blood pressure was continuously monitored (Statham P23 DC pressure transducer) on a Grass Model 7D polygraph recorder. The animals were allowed to stabilize for 1-2 days following the surgical procedures. The animals were permitted access to food and water ad libitum.
Quantitation of SK&F S-106203 in plasma SK&F S-106203 was administered as an initial bolus followed by a continuous infusion for 6 h at the following doses: 0.2mgkg-' + 1.Omgkg-h-', lmgkg-1 + 3mgkg-th-1, or 2mgkg-' + 10mgkg-'h-1. After initiation of the drug infusion, blood samples (approximately 0.5 ml) were collected into heparinized tubes and transferred to Eppendorf microtubes. The blood samples were placed immediately on ice.
Plasma concentrations of SK&F S-106203 were determined in a similar manner to methods previously described . Briefly, the internal standard SK&F 104353 (2(S) -hydroxy -3(R)-(2-carboxyethylthio) -3 -[2-(8-phenyloctyl) phenyl]propanoic acid) was added to the plasma sample (100pl), and extracted twice (750pl) with methyl formate containing 0.5% trifluoroacetic acid. The samples were vortexed, centrifuged at 1000 g and the supernatants combined. The combined supernatants were evaporated to dryness under nitrogen, and resuspended in h.p.l.c. mobile phase. The samples were quantitated on an h.p.l.c. system by a 5 pm NOVAPAK C18 cartridge (Waters Assoc., Inc., Milford, MA). H.p.l.c. effluent was monitored at 215nm with a Kratos Model 783 u.v. detector. SK&F S-106203 and the internal standard were separated isocratically by a solvent system consisting of 59% acetonitrile in 0.1% trifluoroacetic acid at a flow rate of 2mlmin-j. Plasma concentrations of SK&F S-106203 were determined from peak area ratios (compared to internal standard) that were compared to extracted authentic standard curves. The detection limit for quantitation of SK&F S-106203 in plasma was 0.25 pgmlP , and the standard curve of the assay was linear to 100pg mlP-.
Antagonism of leukotriene responses
A separate group of animals, prepared as described above, were used to determine antagonism of LTC4, LTD4 or LTE4 vasopressor responses with SK&F S-106203. On the day of study, animals received LTC4, LTD4 or LTE4 intravenously, at 60min intervals, in one-half log increment doses ranging from 0.17 to 51Onmolkg'1 (i.e., approximately 0.1-300pgkg-1). In this manner, complete dose-response curves were obtained. The acute increase in mean arterial blood pressure following each injection was monitored. LTC4, LTD4 or LTE4 were administered in a volume of 0.1 ml 100 g1 body weight and followed with a 0.5 ml saline flush.
On the following day, animals were administered a bolus followed by an influsion of SK&F S-106203 at the same doses indicated above. At 1 h after the start of the infusion, the doseresponse curve to LTC4, LTD4 or LTE4 was repeated according to the procedures described above. The infusion of SK&F S-106203 was continued until the entire dose-response curve was completed. The highest dose of a peptidoleukotriene studied in the presence of an antagonist was 510 nmol kg-1.
To investigate the specificity of SK&F S-106203 to antagonize vascular peptidoleukotriene responses, animals were injected with arginine vasopressin (30 and lOOngkg-1, i.v.), noradrenaline (100 and 300 ng kg-1, i.v.) or isoprenaline (100 and 300Mg kg-1, i.v.). Each animal was injected with only one agonist, and the two doses of the agonist were given at 1 h intervals. Following the administration of the agonist, SK&F S-106203 was administered as a dose of 2mg kg-1 + 10 mg kg1 h -1. After 1 h, the two doses of the agonist were re-administered during continuous infusion of SK&F S-106203 and the change in blood pressure monitored.
To determine the effects of SK&F S-106203 on thromboxane receptor-mediated responses, animals were anaesthetized with sodium pentobarbitone (30mgkg-1, i.p.) and prepared with catheters as described above. After the animals were allowed to stabilize for 15 min, SK&F S-106203 was administered at a dose of 2mgkg-1 + 10mgkg-1h-. One h after initiation of the infusion, the animals were injected intravenously with the thromboxane mimetic U 46619 (100pgkg-1). Another group of animals was injected with the thromboxane receptor antagonist, daltroban (lOmgkg-1, i.v.), and served as a control group (Smith & McDonald, 1988) .
Materials
The disodium salt of SK&F S-106203 (3(S)(2-carboxyethylthio)-3-[2-(8-phenyloctyl)phenyl] propanoic acid) was dissolved in 0.9% NaCl. The dose of SK&F S-106203 refers to the free acid. LTC4, LTD4 and LTE4 (synthesized at SmithKline Beecham Pharmaceuticals plc, King of Prussia, PA) were dissolved in distilled water and the stock stored at 4°C. On the day of use, a sample was removed, diluted in distilled water and scanned in a spectrophotometer (Beckman DU-50, Somerset, N.J.) from 200-350nm. The absorbance at 282nm was then measured, and the concentration of the sample determined with an extinction coefficient of 40,000 M 1 cm-. An aliquot of the stock was then diluted in 0.9% NaCl and stored on ice until used. D-Penicillamine and isoprenaline (Sigma Chemical Co., St. Louis, MO) were dissolved in 0.9% NaCI. Noradrenaline (Sigma Chemical Co., St. Louis, MO) was dissolved in 0.9% NaCl containing l00#ugmlP1 ascorbic acid. Arginine vasopressin (Sigma Chemical Co., St. Louis, MO) was dissolved in acetic acid at a concentration of 10mgml-', and further diluted in 0.9% NaCl. U 46619 (9,11-dideoxy-1 Ia9a-epoxymethano-prostaglandin F2., Upjohn Diagnostics, Kalamazoo, MI) was initially dissolved in 50% ethanol containing 1.5 mg ml-' NaHCO3, and further diluted in 0.9% NaCl. Daltroban (SmithKline Beecham Pharmaceuticals plc, King of Prussia, PA) was dissolved in 50nm Tris buffer, pH 9.4. All solutions were made fresh on the day of use.
Statistics
All data in the text, figures and table are expressed as the mean + s.e.mean of n observations. Since multiple samples were taken from individual animals, the average plasma concentrations over the course of an infusion were first calculated for individual animals, and then averaged to obtain mean group estimates. Steady-state plasma concentrations of SK&F S-106203 are expressed as the mean of the plasma concentrations of drug determined at 1, 2, 4 and 6 h of infusion. For LTC4 and LTD4 responses, the ED20 was calculated for individual dose-response curves, with the ED20 being the dose of peptidoleukotriene which produced an increase in blood pressure of 20 mmHg. Since LTE4 appeared to be a partial agonist in these preparations, and produced a comparatively small response, the corresponding ED10 dose was calculated. Doseratios were calculated as the quotient of the ED20 (or ED1O for LTE4) dose of an individual experiment in the presence of SK&F S-106203 to the mean ED20 determined from the peptidoleukotriene dose-response curves in the absence of SK&F S-106203. The doses of SK&F S-106203 were 0.2mgkg-1 + 1 mgkg-'h-1 (), l mgkg-' + 3mgkg-1h-' (A), or 2mgkg-' + 10mgkg-1h-' (A). kg-1 h-1, steady-state plasma concentrations of SK&F S-106203 appeared to increase linearly as a function of dose (Figure 2 ), although it appeared that at the highest dose of SK&F S-106203 the increment in plasma concentration was approximately 2-3 fold greater than the increment in dose. The dose-response relationship for LTC4 and the effect of SK&F S-106203 are illustrated in Figure 3 and summarized in Table 1 . LTC4 at a dose of 0.17nmolkg-', i.v. (0.3pgkg-'), produced a threshold vasopressor response and the ED20 was 2.3 + 0.5 nmol kg-1 (n = 10). SK&F S-106203 inhibited the responses to LTC4 in a manner which suggested competitive interaction at the peptidoleukotriene receptor site. Administration of SK&F S-106203 at doses ranging from 1.0-10mgkg-' h-1 produced dose-dependent, parallel and rightward shifts in the dose-response curve. The effect of SK&F S-106203 on the dose-response relationship to LTD4 is illustrated in Figure 3 and summarized in Table 1 . The ED20 for LTD4 was 2.3 + 0.5nmolkg-1 (n= 13). Administration of increasing doses of SK&F S-106203 produced parallel and rightward shifts in the LTD4 dose-response curve. At a dose of 0.2mgkg-' + lmgkg-'h-1, SK&F S-106203 antagonized the LTD4 vasopressor response, with a resultant dose-ratio of 2.5. A dose of t mg kg'-+ 3 mg kg-' h -', which produced a steadystate plasma concentration of 3.2igml-1, did not result in any further shift in the dose-response curve than that produced by a dose of 0.2 mg kg-' + I mg kg-'h -'. However, at a dose of 2mgkg-1 + lOmgkg-'h-1, SK&F S-106203 produced a further shift in the dose-response curve to LTD4, with a dose ratio of 11.4.
The dose-response relationship for LTE4, and the effect of SK&F S-106203, is illustrated in Figure 3 and summarized in Table 1 . LTE4 at a dose of 5.lnmolkg-', i.v., produced a threshold vasopressor response. The ED20 for LTE4 was 30 + 5 nmol kg'-(n = 13). Although the dose-response curves for LTC4, LTD4 and LTE4 were not parallel, the data indicate that LTE4 was 10 to 30 fold less potent than LTC4 or LTD4 at increasing blood pressure in conscious, normotensive rats. Furthermore, within the range of doses used the maximal vasopressor response to LTE4 appeared to be less than that achieved with LTC4 or LTD4. Administration of SK&F S-106203 at doses of 0.2mgkg-1 + lmgkg-1h'-, 1mg kg-1 + 3mgkg-'h-1 or 2mgkg-1+ lOmgkg-'h-' produced dose-dependent rightward shifts in the LTE4 doseresponse curve. SK&F S-106203 at a dose of 1 mg kg-1 + 3mg kg-' h' did not appear to affect the maximal vasopressor response to LTE4, whereas the maximal LTE4 response following SK&F S-106203 at a dose of 2mg kg-1 + l0mgkg-1h-did appear to be depressed. Unfortunately, higher doses of LTE4 could not be administered due to the limited availability of this compound. Table 2 and Figure 4 summarize the experiments to evaluate the specificity of SK&F S-106203 in antagonizing peptidoleukotriene vasopressor responses. Injection of arginine vasopressin or noradrenaline produced the expected increases in arterial blood pressure, and isoprenaline the expected decrease in arterial blood pressure. Administration of SK&F S-106203 (2mgkg-1 + l0mgkg-'h-1) had no significant effects on the cardiovascular responses to these agonists (Table 2) , although these responses were blocked by specific receptor antagonists (i.e., d(CH2)5Tyr(Me)AVP, prazosin, and propranolol). Similarly, administration of SK&F S-106203 did not prevent U 46619-induced sudden death in rats (n = 4). Pretreatment with the thromboxane receptor antagonist, daltroban, at a dose of 10mg kg-, i.v., prevented completely the U 46619-induced sudden death (n = 4). The effects of an LTD4 dipeptidase inhibitor, Dpenicillamine (Huber & Keppler, 1987) , on the LTD4 vasoconstrictor response was investigated. Before the administration of D-penicillamine, an injection of 5.1 nmol kg-' LTD4 produced an increase in blood pressure of 32 + 3 mmHg (n = 9). At 5 and 50min following the administration of 2 nmol kg-' D-penicillamine, LTD4 increased blood pressure by 31 + 3 (n = 9) and 32 + 2 mmHg (n = 9), respectively. There was no statistically significant difference between the initial LTD4 pressor response and those pressor responses elicited following the injection of Dpenicillamine. SK&F S-106203 was administered as a bolus followed by an infusion, at a dose of 2mgkg-1 + 10mgkg-'h-1, beginning 1 h before the final challenge. Vasopressin, noradrenaline and isoprenaline were administered intravenously at the indicated doses. NS: not statistically different.
Discussion
The purpose of this study was to characterize the effects of the selective peptidoleukotriene receptor antagonist, SK&F S-106203, on the vasopressor responses to exogenously administered peptidoleukotrienes in the rat. SK&F S-106203 has been shown to be a potent and highly selective antagonist of peptidoleukotriene responses in guinea-pig tracheal preparations, with a pA2 of 7.9 against LTD4 responses, and a pKB of 7.3 on LTE4 contractions . SK&F S-106203 does not inhibit guinea-pig tracheal contractions produced by carbachol, histamine, U 44069, potassium chloride, PGD2 or PGF2., and does not inhibit cyclic nucleotide phosphodiesterases (Michelassi et al., 1982; Ahmed et al., 1986; Eimerl et al., 1986; Filep et al., 1987) , this study investigated the effects of a continuous infusion of SK&F S-106203 on the vasopressor responses to LTC4, LTD4 and LTE4. The inability to achieve steady-state pharmacokinetics following a bolus administration of drug would preclude a priori any conclusions on the relationship between plasma concentrations and drug effect. As depicted in Figure 1 , the intent of achieving dose-related increases in steady-state plasma concentrations of SK&F S-106203 was in fact accomplished in these studies. At the lower doses of SK&F S-106203, a linear relationship appeared to exist between the dose and plasma concentrations. Thus, a 3 fold increase in dose from I mg kgh-1 h-to 3 mg kg-' h -' was associated with a corresponding increase in steady-state plasma concentrations (i.e., 1 and 3.2pgml-1, respectively). However, at a dose of 10mgkg-1 -1 the corresponding plasma concentration was 23.8pgml-'. The explanation for the deviation from linearity at the highest dose of SK&F S-106203 is not precisely known, but may possibly reflect saturation of the primary clearance mechanism(s) for the drug.
SK&F S-106203 inhibited the responses to LTD4 in a manner which suggests competitive interaction at the peptidoleukotriene receptor site. Administration of SK&F S-106203 at doses of 1-lOmgkg-1 h-produced parallel shifts to the right in the LTD4 dose-response curve. Interestingly, increasing the dose of SK&F S-106203 from 0.2mg kg-1 + lmgkg 1h-1 to lmgkg-1 + 3mgkg-lh-1 did not result in a further shift in the LTD4 dose-response curve. However, an increase in the SK&F S-106203 dose to 10mg kg-1 h-' produced a further increase in the dose-ratio. The resultant dose-response curves, which resemble the theoretical curves obtained for a non-selective agonist acting in a two-receptor system (Lemoine & Kaumann, 1983; Kenakin, 1987) , suggest the existence of two peptidoleukotriene receptor sites mediating the vasopressor effects of LTD4. Similarities in the dose-ratios to the vasopressor responses of LTD4 despite incremental increases in the dose (vis a vis plasma concentrations) of a peptidoleukotriene receptor antagonist has been previously obtained for SK&F S-104353 . These data with ICI 198615 corroborate the observations of Hand et al. (1989) in guinea-pig isolated trachea, and further support their suggestion of two LTD4 receptor subtypes. Therefore, the results with SK&F S-106203 provide additional support for the proposal that the vasopressor responses to LTD4 are mediated by activation of a specific, but possibly heterogeneous high and low affinity LTD4 receptor population.
The possibility that LTD4 receptors may not be comprised of a homogeneous population has been suggested previously (Fleisch et al., 1984) . Fleisch et al. (1982) showed that the pA2 values for FPL 55712 against LTD4 responses were similar in guinea-pig trachea and parenchyma, but different from those of the ileum. Krell et al. (1983) suggested the existence of two LTD4 receptors in guinea-pig trachea based upon different affinities for FPL 55712. Aharony et al. (1989) suggested subtypes of LTD4 receptors on guinea-pig lung membranes based on results from receptor binding studies. In conjunction, the results in pulmonary tissue provide considerable support for the proposal of heterogeneity within the LTD4 receptor.
Although thromboxane appears to be the final mediator of peptidoleukotriene responses in the lung (Folco et al., 1981; Piper & Samhoun, 1981; Ueno et al., 1982) , the systemic effects of the peptidoleukotrienes appear to be independent of the effects of thromboxane (Ahmed et al., 1986; . Furthermore, the vasopressor responses to LTD4 in the rat do not appear to be explained by the contribution of prostaglandins, thromboxane, catecholamines, angiotensin or vasopressin since indomethacin, prazosin, phentolamine, saralasin, the thromboxane receptor antagonist daltroban, or the V1-selective arginine vasopressin receptor antagonist d(CH2)5Tyr(Me)AVP have no effect on the systemic responses to either LTC4 or LTD4 (Badr et al., 1984; Filep et al., 1987; . The present study provides further support for the supposition of LTD4 receptor heterogeneity by demonstration of a similarity in LTD4 dose-ratios despite increasing plasma concentrations of SK&F S-106203. The observations with' SK&F 104353 ICI 198615 (Hand et al., 1989; In summary, the results of this study indicate that SK&F S-106203 is an effective antagonist of LTC4, LTD4 and LTE4 vascular responses in the conscious rat. A peptidoleukotriene receptor antagonist with high oral bioavailability, such as SK&F S-106203, could be useful for probing the role of peptidoleukotrienes in respiratory and cardiovascular disorders. Moreover, the results of the present study suggest that SK&F S-106203 pharmacologically differentiates two LTD4 receptor subtypes on vascular smooth muscle: one characterized as a high affinity receptor site for LTD4, and a second receptor subtype with somewhat lower affinity. This observation is consistent with previous studies with SK&F 104353 and ICI 198,615 (Hand et al., 1989; . Although LTD4 can activate both receptor subtypes, further studies will be required in order to determine the importance and significance of these receptor subtypes.
